A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension

Trial Profile

A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Losartan
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Arbor Pharmaceuticals
  • Most Recent Events

    • 25 Jan 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018, according to ClinicalTrials.gov record.
    • 25 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2018, according to ClinicalTrials.gov record.
    • 25 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top